British drug major AstraZeneca Plc. (AZN.L,AZN) announced Thursday that it has entered into a definitive agreement to acquire Amolyt Pharma, a clinical-stage biotechnology company focused on rare endocrine diseases.
Under the deal terms, AstraZeneca will buy Amolyt Pharma for a total consideration of up to $1.05 billion, on a cash and debt free basis.
The consideration includes $800 million upfront at deal closing. There will also be the right for Amolyt Pharma's shareholders to receive an additional contingent payment of $250 million payable upon achievement of a specified regulatory milestone.
The deal is expected to close by the end of the third quarter of 2024, subject to the satisfaction of customary closing conditions in the acquisition agreement, including regulatory clearances.
Amolyt Pharma develops eneboparatide (AZP-3601), a Phase III investigational therapeutic peptide with a novel mechanism of action designed to meet key therapeutic goals for hypoparathyroidism.
AstraZeneca expects the proposed acquisition will bolster the Alexion, AstraZeneca Rare Disease late-stage pipeline and expand on its bone metabolism franchise.
Marc Dunoyer, Chief Executive Officer, Alexion, AstraZeneca Rare Disease, said, "As leaders in rare disease, Alexion is uniquely positioned to drive the late-stage development and global commercialisation of eneboparatide, which has the potential to lessen the often debilitating impact of low parathyroid hormone and avoid the risks of high-dose calcium supplementation. We believe this programme, together with Amolyt's talented team, expertise and earlier pipeline, will enable our expansion into rare endocrinology."
For More Such Health News, visit rttnews.com
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.